This study aims at understanding Coronavirus disease 2019 (COVID-19) has rapidly spread worldwide and has now become a global pandemic. As of early November, in the USA alone more than 11.6 million people have been infected, with 250 000 fatalities. Severe cases of COVID-19 can lead to development of acute respiratory distress syndrome (ARDS), septic shock, and multiorgan failure.1 In some critically ill patients with COVID-19, cytokine storm has been reported to increase mortality. This storm results from the release of pro-inflammatory cytokines and chemokines. Metabolic syndrome (MetS), which is manifested with obesity, hypertension, hyperglycemia, and dyslipidemia, is characterized by a prothrombotic and pro-inflammatory state with elevated C-reactive protein and interleukin-6.5 These systemic inflammatory markers are the main risk factors for the development of macrovascular complications that lead to significant increase in morbidity and mortality. The prevalence of MetS in the USA, according to the National Health and Nutrition Examination Survey (NHANES).

Reference link-